Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

Fiona Powrie © Thomas S. G. Farnetti Wellcome

Wellcome is a global charitable foundation that funds thousands of researchers. It works with academia, philanthropy, businesses, governments, civil society and the public around the world to support science's role in solving health challenges.

With a background in immunology and translational research, Fiona has been a member of Wellcome's Board of Governors since January 2018. She will take up her post in January 2022 from Professor Mike Ferguson, who is stepping down from the Board and Wellcome after 10 years.

Following her appointment, Fiona said: "It is an honour and privilege to serve Wellcome as Deputy Chair. It's an organisation that I've always admired from the beginning of my career. I look forward to working with everyone at Wellcome to help deliver our new strategy that harnesses science and research to improve health for all."

Commenting on her appointment, Julia Gillard, Chair of Wellcome, said: "Fiona's new role as Deputy Chair will allow us to benefit even more from her experience in science and research. I look forward to working with her to drive forward Wellcome's mission to solve the urgent health challenges facing everyone."

Professor Andrew Carr, Head of Department at NDORMS, University of Oxford said: "We send our warm congratulations to Fiona on this new appointment. Fiona's pioneering work in immunology has contributed to a better understanding, prevention and treatment of disease which will help advance global scientific discovery research at Wellcome."

Similar stories

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Professor Chris Buckley joins the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.

The Kennedy Institute scoops sustainability award

A new roof extension was awarded the 2021 Green Award for Sustainability by the Oxford Preservation Trust alongside a Certificate in the New Building category.

The Kennedy Institute Student Symposium returns for its 5th year

A two-day student symposium returned to the Kennedy Institute bringing together students and peers from across the department to discuss their latest research.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.